US begins trials for artificial blood in heart surgery:
This article was originally published in Clinica
Executive Summary
Canadian company Hemosol is to begin Phase II clinical trials in the US of its oxygen-carrying artificial blood, Hemolink, in patients undergoing coronary artery bypass grafting surgery (CABG). Researchers will examine whether using Hemolink as a red blood cell substitute during CABG will lessen some of the adverse effects associated with the bypass procedure, such as bleeding disorders and blood pressure instability. Phase II trials of Hemolink in patients undergoing CABG are already underway in the UK and Canada. Toronto-based Hemosol is one of several companies developing blood substitutes (see Clinica No 812, p 14).
You may also be interested in...
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.